Senesco Presents Pre-Clinical Stability and Biological Activity Data on SNS-01 at the 2009 AACR-NCI-EORTC Molecular Targets and

NEW BRUNSWICK, N.J., Nov. 12  /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) announced today that Catherine Taylor, one of the Company's funded researchers, will be presenting pre-clinical stability and biological activity data on SNS-01, Senesco's multiple myeloma drug candidate, at the 2009 American Association for Cancer Research (AACR)-National Cancer Institute (NCI)-European Organization for Research and Treatment of Cancer (EORTC) Molecular Targets and Cancer Therapeutics Conference.  Ms. Taylor is a member of the Department of Biology at the University of Waterloo, Ontario, Canada.  The conference will take place from Sunday, November 15th through Thursday, November 19th, in Boston, MA.  Ms. Taylor's abstract will be presented at a session entitled, "Gene Therapies", which will run from 12:30 PM until 2:30 PM on Monday, November 16th.

The conference, hosted by AACR, NCI and EORTC, will bring together academics and scientists and representatives from the pharmaceutical industry to discuss innovation in drug development, target selection and the impact of new discoveries in molecular and cell biology.  The event has been organized to reflect the many recent advances in the early development of promising new compounds, which are in different levels of preclinical and clinical development.

About Senesco Technologies, Inc.

Senesco Technologies, Inc. is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer treatments. Delaying apoptosis may have applications to certain inflammatory and ischemic diseases. Senesco takes its name from the scientific term for the aging of plant cells: senescence. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress. The Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products.

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the ability of the Company to consummate additional financings; the development of the Company's gene technology; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs and joint ventures; the success of the Company's license agreements; the acceptance by the market of the Company's products; success of the Company's preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, the Company's ability to meet its funding milestones under its financing transaction, the Company's ability to continue to comply with the continued listing standards of the AMEX, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

  Company Contact:                  Investor Relations Contact:
  Senesco Technologies, Inc.        FD
  Bruce Galton                      Brian Ritchie
  Chief Executive Officer           ()
  ()             [phone]
  [phone]


DATASOURCE: Senesco Technologies, Inc.



CONTACT:  Bruce Galton, Chief Executive Officer, Senesco Technologies,

Inc., , [phone]; or Investor Relations: Brian

Ritchie, FD, , [phone]



Web Site:  http://www.senesco.com/ 

Copyright